Education
About Us
Working with TipRanks
Follow Us
Pacira (PCRX)
:PCRX
PCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.16 - $27.64
Previous CloseN/A
Volume54.84K
Average Volume (3M)559.77K
Market Cap
$1.02B
Enterprise Value$1.30B
Total Cash (Recent Filing)$300.48M
Total Debt (Recent Filing)$492.28M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Oct 30, 2025EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding46,304,670
10 Day Avg. Volume677,893
30 Day Avg. Volume559,774
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio4.87
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue1.84
Enterprise Value/Gross Profit3.16
Enterprise Value/Ebitda-61.28
Forecast
1Y Price Target
$27.50Price Target Upside22.01% Upside
Rating ConsensusHold
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Patent Litigation SettlementPCRX shares have had a strong performance after the Company settled patent litigation for Exparel.
Regulatory Reimbursement ChangesThe NOPAIN reimbursement change, which removes Exparel from the surgical bundle and offers additional reimbursement incentives, could impact pricing strategy positively.
Share Repurchase ProgramA new $300MM share repurchase program has been announced.
Bears Say
Competitive PressuresThere are concerns about competitive pressures impacting Pacira's market share.
Sales Growth UncertaintyInvestors looking for an inflection in Exparel sales growth, but this could take longer than hoped as the NOPAIN Act is likely not a 'light switch' nor the 'silver bullet'.
Top-Line PerformancePCRX's start to 2025 is disappointing in terms of the top-line which came in at $168.9MM, short of the Street's $176MM.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira’s price range in the past 12 months?
Pacira lowest stock price was $11.16 and its highest was $27.64 in the past 12 months.
What is Pacira’s market cap?
Pacira’s market cap is $1.02B.
When is Pacira’s upcoming earnings report date?
Pacira’s upcoming earnings report date is Oct 30, 2025 which is in 83 days.
How were Pacira’s earnings last quarter?
Pacira released its earnings results on Aug 05, 2025. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.03.
Is Pacira overvalued?
According to Wall Street analysts Pacira’s price is currently Undervalued.
Does Pacira pay dividends?
Pacira does not currently pay dividends.
What is Pacira’s EPS estimate?
Pacira’s EPS estimate is 0.66.
How many shares outstanding does Pacira have?
Pacira has 46,304,670 shares outstanding.
What happened to Pacira’s price movement after its last earnings report?
Pacira reported an EPS of $0.74 in its last earnings report, beating expectations of $0.71. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Pacira?
Currently, no hedge funds are holding shares in PCRX
Pacira Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$27.50 (22.01% Upside)
$27.50 (22.01% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 26.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $775.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.69%
12-Months-Change
Fundamentals
Return on Equity
-12.27%
Trailing 12-Months
Asset Growth
0.21%
Trailing 12-Months
Company Description
Pacira
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
PCRX Company Deck
PCRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant strategic wins, including the EXPAREL patent settlement and strong sales growth. However, some challenges remain, particularly in the transition of sales teams and adoption of new reimbursement pathways.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$27.50
▲(22.01% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
2.69% Insiders
23.51% Mutual Funds
1.04% Other Institutional Investors
41.05% Public Companies and
Individual Investors